Researchers sought to compare the safety and efficacy of pirtobrutinib monotherapy vs bendamustine plus rituximab among treatment-naïve patients with CLL/SLL.
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Patients were randomly ...
BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...
Analysis of readmission rates, length of stay and mortality among bone marrow transplant and CAR-T patients in a rural state. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Acalabrutinib shows improved cardiovascular safety over ibrutinib, reducing atrial fibrillation and hypertension risks in CLL patients. Real-world data confirm ELEVATE-RR trial results, highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results